Atea Pharmaceuticals (AVIR) Change in Account Payables (2019 - 2026)

Atea Pharmaceuticals' Change in Account Payables history runs 8 years deep, the most recent figure standing at -$3.5 million for Q1 2026.

• In Q1 2026, Change in Account Payables fell 219.46% year-over-year to -$3.5 million; the TTM figure through Mar 2026 stood at $2.1 million (up 114.97% YoY), while the FY2025 annual figure was $8.5 million, up 4019.9% from the prior year.
• Change in Account Payables was -$3.5 million for Q1 2026 at Atea Pharmaceuticals, down from $9.4 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $16.9 million in Q1 2024 to a low of -$15.7 million in Q2 2024.
• Historically, Change in Account Payables has averaged $288941.2 across 5 years, with a median of $315000.0 in 2024.
• The sharpest annual moves came in 2024 and 2025: Change in Account Payables jumped 1012.21% in 2024, then plunged 1791.75% in 2025.
• A 5-year view of Change in Account Payables shows it stood at $1.4 million in 2022, then jumped by 169.16% to $3.9 million in 2023, then sank by 134.4% to -$1.3 million in 2024, then jumped by 810.63% to $9.4 million in 2025, then slumped by 137.1% to -$3.5 million in 2026.
• The last three Change in Account Payables figures came in at -$3.5 million (Q1 2026), $9.4 million (Q4 2025), and -$5.3 million (Q3 2025), per Business Quant data.